i3 Verticals price target lowered to $25 from $27 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on i3 Verticals (IIIV) to $25 from $27 and keeps an Equal Weight rating on the shares. The firm thinks the sale of i3’s lower-margin and slower growing Healthcare RCM business can be beneficial long-term, though noise around recent transactions may make it hard to get comfortable with underlying growth trends following the sale of Merchant, the analyst tells investors.